Show simple item record

dc.contributor.authorCalderón-Pérez, Lorena
dc.contributor.authorGosalbes, Maria José
dc.contributor.authorYuste, Silvia
dc.contributor.authorValls, Rosa M.
dc.contributor.authorPedret, Anna
dc.contributor.authorLlauradó, Elisabet
dc.contributor.authorJimenez-Hernandez, Núria
dc.contributor.authorArtacho, Alejandro
dc.contributor.authorPla-Pagà, Laura
dc.contributor.authorCompanys, Judit
dc.contributor.authorLudwig, Iziar A.
dc.contributor.authorRomero Fabregat, Mª Paz
dc.contributor.authorRubió Piqué, Laura
dc.contributor.authorSolà, Rosa
dc.description.abstractHypertension is an independent and preventable risk factor for the development of cardiovascular diseases, however, little is known about the impact of gut microbiota composition in its development. We carried out comprehensive gut microbiota analysis and targeted metabolomics in a cross-sectional study of 29 non-treated hypertensive (HT) and 32 normotensive (NT) subjects. We determined fecal microbiota composition by 16S rRNA gene sequencing and bacterial functions by metagenomic analysis. The microbial metabolites analysed were short chain fatty acids (SCFA) both in plasma and feces, and trimethylamine N-oxide (TMAO) in plasma. The overall bacterial composition and diversity of bacterial community in the two groups were not significantly different. However, Ruminococcaceae NK4A214, Ruminococcaceae_UCG-010, Christensenellaceae_R-7, Faecalibacterium prausnitzii and Roseburia hominis were found to be significantly enriched in NT group, whereas, Bacteroides coprocola, Bacteroides plebeius and genera of Lachnospiraceae were increased in HT patients. We found a positive correlation between the HT-associated species and systolic and diastolic blood pressure after adjusted for measured confounders. SCFA showed antagonistic results in plasma and feces, detecting in HT subjects significant higher levels in feces and lower levels in plasma, which could indicate a less efficient SCFA absorption. Overall, our results present a disease classifier based on microbiota and bacterial metabolites to discriminate HT individuals from NT controls in a first disease grade prior to drug treatment.ca_ES
dc.description.sponsorshipWe wish to acknowledge the support of the Institut d’Investigació Sanitària Pere Virgili (IISPV) and the EURECAT-Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut (Reus, Spain), the University of Lleida through the SY grant, the LR Sara Borrell postdoctoral grant (CD14/00275), and AP Torres Quevedo contract (Subprograma Estatal de Incorporación, Plan Estatal de Investigación Científica y Técnica y de Innovación). LC was granted by Ayudas Para La Promoción De Empleo Joven E Implantación De La Garantía Juvenil En I + D + I (PEJ-2014-A-67028). NFOC-Salut group is a consolidated research group of Generalitat de Catalunya, Spain (2017 SGR522).ca_ES
dc.publisherSpringer Natureca_ES
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofScientific Reports, 2020, vol. 10, p. 6436ca_ES
dc.rightscc-by (c) Calderón-Pérez, Lorena et al., 2020ca_ES
dc.subjectMarcadors predictiusca_ES
dc.titleGut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional studyca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c) Calderón-Pérez, Lorena et al., 2020
Except where otherwise noted, this item's license is described as cc-by (c) Calderón-Pérez, Lorena et al., 2020